Devin Boehm

Devin Boehm

Auto-generated profile, based on publicly available information

Devin Boehm

Northwestern University, Feinberg School of Medicine, Chicago, IL, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
SSShayak Samaddar
Shayak Samaddar
JMJoshua Mazur
Joshua Mazur
DBDevin Boehm
Devin Boehm
David H ThompsonDavid H Thompson
David H Thompson
Background: Bladder cancer is the fourth most common cancer in men and eleventh most common in women. Combination therapy using a gene and chemotherapeutic drug is a potentially useful strategy for treating bladder cancer in cases where a synergistic benefit can be achieved successfully. This approach relies on developing drug combinations using carrier systems that can load both hydrophilic genes and hydrophobic drugs. Ideally, the formulation for carrier system should be free of traditional high shear techniques such as sonication and extrusion to reduce shear-induced nucleic acid strand breakage. Moreover, the system should be able to protect the nucleic acid from enzymatic attack and deliver it specifically to the tumor site. Materials and methods: A dual payload carrier system that was formulated using a simple flow mixing technique to complex anionic plasmid (EGFP-NLS) using a cationic polymer (CD-PEI2.5kD) followed by coating of the polyplex using lipid membranes. The resulting lipid-coated polyplex (LCP) formulations are targeted to bladder cancer cells by employing a bacterial adhesive peptide sequence, RWFV, that targets the LCP to the tumor stroma for efficiently delivering reporter plasmid, EGFP-NLS and a model small molecule drug, pyrene, to the cancer cells. Results: Encapsulation efficiency of the peptide targeted carrier for the plasmid was 50% ± 0.4% and for pyrene it was 16% ± 0.4%. The ability of the targeted LCP to transfect murine bladder cancer cells was 4-fold higher than LCP bearing a scrambled peptide sequence. Fluorescence of cells due to pyrene delivery was highest after 4 hrs using targeted LCP. Finally, we loaded the peptide targeted LCP with anti-cancer agent, curcumin. The targeted formulation of curcumin resulted in only 45% viable cancer cells at a concentration of 5 μg/mL, whereas the empty and non-targeted formulations did not result any significant cell death. Conclusion: These results demonstrate the specificity of the targeting peptide sequence in engaging tumor cells and the utility of the developed carrier platform to deliver a dual payload to bladder tumor cells.

1 August 2025 in Translational Andrology and Urology
Verified
Journal Article
Open access
PDF file
DBDevin Boehm
Devin Boehm
ASAbigail R. Smith
Abigail R. Smith
SMSarah A. Mansfield
Sarah A. Mansfield
KFKathryn E. Flynn
Kathryn E. Flynn
RFRichard J. Fantus
Richard J. Fantus
JGJames W. Griffith
James W. Griffith
Background: Erectile function (EF) and its associated covariates have not been extensively studied in a large covariate of patients seeking treatment for lower urinary tract symptoms (LUTS). Our objective is to determine the relationship between urinary symptoms and comorbidities with erectile dysfunction (ED) in 447 treatment-seeking men with LUTS. Methods: Data from the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) observational cohort study were analyzed using multivariable logistic regression models to quantify the relationship between LUTS and ED. Models also included anxiety, depression, obesity, cardiovascular disease (CVD), diabetes, and medication use. Results: Men reporting sexual activity were younger (median age 61 vs. 69 years) and had lower prevalence of diabetes and CVD (13% and 15%, respectively) compared with men reporting no sexual activity (24% for diabetes and 27% for CVD). Among sexually-active participants, higher odds of ED were associated with diabetes [odds ratio (OR) =2.4; 95% confidence interval (CI): 1.1–5.0], age (per 5 years, OR =1.4; 95% CI: 1.2–1.6), urinary incontinence (UI) (OR =1.2; 95% CI: 1.0–1.4), and anxiety (per 10 T-score units, OR =1.4; 95% CI: 1.0–2.1). Low erectile confidence was related to older age in non-sexually-active men (per 5 years, OR =1.5; 95% CI: 1.2–1.8). In sexually-active men, anxiety (per 10 T-score units, OR =1.6; 95% CI: 1.1–2.4), age (OR =1.3; 95% CI: 1.2–1.5), PDE5-inhibitor use (OR =2.1, 95% CI: 1.0–4.3), and diabetes (OR =2.2; 95% CI: 1.1–4.7) were also associated with low erectile confidence. Conclusions: The association of UI with ED highlights the importance of screening men with UI for ED. Modifiable health variables, such as anxiety and diabetes, were related to ED and erectile confidence in treatment-seeking men with LUTS.